TISCO Biotechnology Healthcare Fund
(TBIOTECH)

General Information

- **Fund Type**: Foreign Equity Fund (Feeder Fund), Healthcare Sector Fund
- **AIMC Category**: Health Care
- **Registered Date**: 12 March 2020
- **Subscription & Redemption Period**: Every working day during 8:30 - 15:00
- **Minimum Amount for Subscription**: 1,000 Baht
- **Minimum Amount for Redemption**: None
- **Settlement Day**: T+7 (after the redemption date)
- **Dividend Policy**: None

Investment Policy

The fund shall invest at least 80% of its NAV in Polar Capital Funds plc - Biotechnology Class I US Dollar (master fund), managed by Polar Capital LLP, which has an investment policy to invest at least 51% of its NAV in Biotechnology, Diagnostics, Life Sciences Tools companies worldwide. The fund may invest in derivatives for hedging purpose, depending on the discretion of the management company as appropriate to the circumstances of each moment. Currently, the fund will invest in derivatives for hedging foreign exchange rate risk about 90% of the foreign investment assets.

Fees and Expenses

- **Fee Charged to the Fund (% p.a. of NAV)**
  - Management Fee: 1.0700%
  - Trustee Fee: 0.032100%
  - Registrar Fee: 0.171200%
- **Fee Charged to Unit holders (% of investment unit value)**
  - Front-end Fee: 1.00%
  - Back-end Fee: None
  - Switching In Fee: None
  - Switching Out Fee: None

Note: The fees and expenses charged above include VAT, specific business tax or any other taxes related with fees and expenses.

Warnings & Recommendation

1. Investment contains some degree of risks. The investor should study the fund’s prospectus before investing.
2. The fund has specific investment in healthcare sector, so it may has risk and price volatility higher than general mutual funds with diversification in several industries. Investors should study the healthcare sector information for investment decisions.
3. The fund does not have fully hedging policy against foreign exchange rate, therefore, it may have opportunity loss or receive additional gain from a decrease or an increase in foreign exchange rate and investors may receive redemption proceeds less than their initial investment amount.
4. The Management Company reserves the right to reject or halt the subscription order, allocation and/or transferring of investment units directly or indirectly for US citizens.

Details of Portfolio

- **Assets Allocation**
  - Polar Capital Funds plc - Biotechnology FUND 98.78%

Top 5 Holding (By Company)

<table>
<thead>
<tr>
<th>Securities/Issuer</th>
<th>Proportion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Polar Capital Funds plc - Biotechnology</td>
<td>98.78%</td>
</tr>
</tbody>
</table>

Past Performance and Benchmark Return

Past Performance and Benchmark Return

<table>
<thead>
<tr>
<th>Fund Name</th>
<th>Benchmark: An average of 1) Master fund’s performance, calculating in THB term (95%) 2) an average of (less than 5 million Bath) 1-year personal fixed deposit (KTBANK, BBL, and SCB) after tax (5%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fund Return</td>
<td>8.78%</td>
</tr>
<tr>
<td>Benchmark Return</td>
<td>8.78%</td>
</tr>
</tbody>
</table>

Fees Charged to Unit holders (% of investment unit value)

- Front-end Fee: 14.25%
- Back-end Fee: None
- Switching In Fee: None
- Switching Out Fee: None

Fees Charged to the Fund (% p.a. of NAV)

- Management Fee: 1.0700%
- Trustee Fee: 0.032100%
- Registrar Fee: 0.171200%


References:

- TISCO Biotechnology Healthcare Fund
- General Information
- Investment Policy
- Fees and Expenses
- Warnings & Recommendation
- Details of Portfolio
- Top 5 Holding (By Company)
- Past Performance and Benchmark Return
- Fees Charged to Unit holders (% of investment unit value)
- Fees Charged to the Fund (% p.a. of NAV)

As of 30 June 2020